Perspectives of vaccination with 13!valent pneumococcal vaccine in adults with chronic respiratory diseases

Abstract

Aim. The aim of this study was to investigate safety and clinical efficacy of 13valent conjugated pneumococcal vaccine (PCV13) and 23valent poly saccharide pneumococcal vaccine (PPV23) in patients with chronic obstructive pulmonary disease (COPD) and asthma and to assess impact of vac cination on quality on life. Methods. This was a prospective comparative study. Clinical efficacy and safety were evaluated using data on systemic and local adverse reactions during a month after vaccination, changes in lung function and quality of life (QoL in 6 months after vaccination. Lung function was assessed before and 1 and 6 months after vaccination. QoL was measured before and 6 months after vaccination using CAT test in COPD patients and ACQ ques tionnaire in asthma patients. Results. The study involved 58 patients with COPD and 59 patients with asthma. Of them, 33 and 34 patients, respectively, were vaccinated with PCV13 and 25 patients of each group were vaccinated with PPV23. A rate of systemic and local adverse reactions did not differ significantly between patients vaccinated with PCV13 or PPV23. Patients with both COPD and asthma vaccinated with PCV13 demonstrated more significant increase in FEV1. QoL improved in all vaccinated patients. Worsening of the disease was not noted in any patient. Conclusion. In patients with COPD and asthma, lung function tended to improvement and QoL significantly improved in 6 months after vaccina tion with PCV13 or PPV23. Both vaccines were well tolerated.